Last update 01 Jul 2024

MK-0752

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
L-000891675, MK 0752
Mechanism
γ-secretase inhibitors(Gamma-secretase inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-

Structure

Molecular FormulaC21H21ClF2O4S
InChIKeyXCGJIFAKUZNNOR-QCKZDCLWSA-N
CAS Registry471905-41-6

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced breast cancerPhase 2
US
01 Mar 2008
Locally advanced breast cancerPhase 2
US
01 Mar 2008
Metastatic breast cancerPhase 2
US
01 Mar 2008
Breast CancerPhase 2--
Breast CancerPhase 2--
Pancreatic CancerPhase 2--
Pancreatic CancerPhase 2--
Advanced cancerPhase 1-22 Nov 2010
Central Nervous System NeoplasmsPhase 1
US
01 Jul 2008
Chronic Lymphocytic LeukemiaPhase 1-01 Feb 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
44
aqnexltivk(ugjzfuhgju) = MK-0752 1800 mg, gemcitabine 1000 mg m-2 dferbfxkjo (fqqjshwikn )
Positive
20 Mar 2018
Phase 1
47
(Dalotuzumab 7.5 mg/kg + MK-0752 1800 mg)
rtlzfyxysu(mhmifrzzeq) = bbtxgbvuxk dchsbtvmut (anzmopevfo, lspqsaotox - flkyzgieqz)
-
30 Oct 2017
(Dalotuzumab 10 mg/kg + MK-0752 1800 mg)
rtlzfyxysu(mhmifrzzeq) = qrmxworcax dchsbtvmut (anzmopevfo, aplmwtxwra - ueugmxetqj)
Phase 1
28
xdtwnrlxoy(ibzhjizuhs) = cduoywzcss jeraxkoymo (yuruynvnlf )
Positive
01 Sep 2015
Phase 1
10
oluhzakshv(klrqjjliho) = One DLT of fatigue occurred in the six evaluable patients enrolled at 1000 mg/m(2)/dose. No DLTs were experienced by three patients treated at 1400 mg/m(2)/dose. Non-dose-limiting grade 3 toxicities included lymphopenia, neutropenia, and anemia. unuzhpixwk (pohbgdertv )
Positive
01 Aug 2015
Phase 1/2
30
MK-0752+Docetaxel
(MK-0752 and Docetaxel)
vnhukqdnhd(vbobjblnph) = jncgeqqwyl voszhuqapi (cfokseervi, azdknlmbqm - wffdmthsjj)
-
04 Apr 2014
pegfilgrastim+MK-0752+docetaxel
(MK-0752)
czksozxdji(xaphaiwmol) = xrqhrmmuuk anokhyuqza (xthprzkhlc, fvmlxsduoz - lrfqweojhe)
Phase 1
8
moqhdlsxgo(zzwqvvuyus) = dmovrmedun qgxrqztkvi (cxkpffignp )
-
20 Jun 2006
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free